While small gains were made in the hip and trauma business, the company reported larger declines in the spine and knee lines. Here is the breakdown for Johnson & Johnson’s orthopedic sales:
1. Orthopedics overall: J&J reported $2.2 billion in third quarter sales, flat from the same period last year. For the nine months end, orthopedic sales were down 0.4 percent, driven by slow international sales.
2. Hips: Hip sales were up 1.5 percent for the quarter, hitting $328 million. The U.S. market drove hip sales with 2.6 percent growth over the same period last year. For the nine months end, hip sales were up 1.9 percent to $1 billion.
3. Knees: A huge drop — 6.8 percent — in international knee sales drove the 3.4 percent decline in worldwide knee sales for the third quarter. J&J reported $348 million in knee sales for the quarter and $1.1 billion for the nine months end, which was a 0.3 percent drop from the first nine months of 2016. U.S. knee sales dropped 1.3 percent in the quarter.
4. Trauma: Worldwide trauma sales were up 3.9 percent for the third quarter, hitting $662 million. As opposed to the company’s knee sales, international trauma sales jumped 6.5 percent in the quarter to $264 million. For the nine months end, trauma sales grew 1.7 percent to nearly $2 billion.
5. Spine and other: U.S. spine sales suffered in the third quarter, declining 5.2 percent year-over-year. The drop in U.S. sales was partially offset by 1.8 percent growth in international spine and other sales, but worldwide sales were down 2.2 percent in the quarter, reaching just $918 million. For the nine months end, spine and other sales dropped 2.6 percent to $2.8 billion.
More articles on orthopedic devices:
Arthrex to build $30M manufacturing plant in SC: 5 insights
Amedica earns extension to demonstrate Nasdaq listing compliance
NuVasive earns expanded FDA clearance for TLX interbody system
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
